METHODS AND DEVICES FOR ORTHOVOLTAGE OCULAR RADIOTHERAPY AND TREATMENT PLANNING

• US 20110081001A1
• Filed: 09/21/2010
• Published: 04/07/2011
• Est. Priority Date: 12/23/2007
• Status: Active Grant

• Current Assignee: Carl Zeiss Meditec Incorporated (Carl-Zeiss-Stiftung)
• Original Assignee: Oraya Therapeutics, Inc.
• Inventors: Arnoldussen, Mark, Liang, Junzhong, Gertner, Michael, Hansen, Steven D., Chell, Erik
• Granted Patent: US 8,494,116 B2
• Time in Patent Office: Days
• US Class Current: 378/65
• CPC Class Codes: A61N 2005/1091 Kilovoltage or orthovoltage range photons
• CPC Class Codes: A61N 5/1017 Treatment of the eye, e.g. for "macular degeneration"
• CPC Class Codes: A61N 5/103 Treatment planning systems
• CPC Class Codes: A61N 5/1037 taking into account the movement of the target, e.g. 4D-image based planning
• CPC Class Codes: A61N 5/1064 for adjusting radiation treatment in response to monitoring

Abstract

A method, code and system for planning the treatment a lesion on or adjacent to the retina of an eye of a patient are disclosed. There is first established at least two beam paths along which x-radiation is to be directed at the retinal lesion. Based on the known spectral and intensity characteristics of the beam, a total treatment time for irradiation along each beam paths is determined. From the coordinates of the optic nerve in the aligned eye position, there is determined the extent and duration of eye movement away from the aligned patient-eye position in a direction that moves the patient'"'"'s optic nerve toward the irradiation beam that will be allowed during treatment, while still maintaining the radiation dose at the patient optic nerve below a predetermined dose level.

Claims

1. A treatment planning method for treating a lesion at or adjacent to the retina of an eye of a patient, by directing X-radiation at the lesion in a patient'"'"'s eye, based on an aligned patient-eye position, along at least two treatment beam paths from a source of a collimated x-radiation beam, comprising:

(a) determining, based on known spectral and intensity characteristics of a source beam along the treatment beam paths and from coordinates of the lesion in the aligned patient-eye position, a total treatment time for irradiation along the beam paths that is effective to produce a desired radiation dose at the lesion, and

(b) determining, based on known spectral and intensity characteristics of the source beam along the beam paths and from coordinates of the optic nerve in the aligned patient-eye position, an extent and duration of eye movement, away from the aligned patient-eye position in a direction that moves the patient'"'"'s optic nerve toward the irradiation beam, that will be allowed during treatment, while maintaining a radiation dose at the patient optic nerve below a predetermined dose level.

2. The method of claim 1, wherein the retinal lesion includes one of macular degeneration, drusen, a tumor, and a vascular abnormality, and further comprising determining the coordinates of the lesion and the optic nerve in an external coordinate system.

3. The method of claim 1, wherein the retinal lesion includes macular degeneration, and further comprising determining coordinates of the macula and the optic nerve in an external coordinate system.

4. The method of claim 1, wherein the aligned patient-eye position places the optical axis of the eye in alignment with an axis normal to the cornea of the eye with the patient looking straight ahead.

5. The method of claim 1, further comprising determining, for the source of collimated x-radiation beam,

(i) at least one of a beam-source collimator configuration that is based on an X-ray emission source-to-target distance, a collimator exit aperture-to-body surface distance, an emission or anode source size, and a collimator exit aperture size that is calculated to provide an X-ray beam-spot at the retina having a diameter or characteristic dimension to the 80% isodose of less than about 8 mm or a penumbra width between the 80% isodose and the 20% isodose of less than about 40% of the beam-spot diameter or beam spot characteristic dimension;

and

(ii) a maximum photon energy and a beam filtration configuration to provide a maximum photon energy between 25-150 keV.

6. The method of claim 5, wherein the maximum photon energy and beam filtration provide a sclera surface-to-retina target dose ratio for the beam of less than N:

1, where N is the number of established beams.

7. The method of claim 1, further comprising establishing at least three beam paths having a total beam angular divergence of between 20-60 degrees.

8. The method of claim 1, further comprising establishing a plurality of beam paths produced by a continuously moving beam source along an arcuate path.

9. The method of claim 1, wherein the determining a total treatment time comprises:

(i) measuring an ocular dimension of the patient'"'"'s eye,

(ii) determining a model of the eye that includes the coordinates of eye features, including the macula and optic nerve, and a virtual ocular medium to a measured ocular dimension, and

(iii) determining, from a known distance of travel of the beam within the model along each path and from the virtual ocular medium through which the beam travels, a dose of radiation from the source to be delivered along each path to produce the desired radiation dose at the macula of the patient'"'"'s eye.

10. The method of claim 1, wherein the determining an extent and duration of eye movement comprises determining, from a known distance of travel of the beam within the model along each beam path and from the virtual ocular medium through which the beam travels, a dose of radiation that is received by the optic nerve as a function of eye movement in a direction that moves the patient'"'"'s optic nerve toward the irradiation beam.

11. Non-transitory machine-readable medium which operates with a computer to execute machine-readable instructions for performing the steps in a treatment planning method for treating a lesion at or adjacent to the retina of an eye of a patient, by directing X-radiation at the lesion in a patient'"'"'s eye, based on an aligned patient-eye position, along at least two treatment beam paths from a source of a collimated x-radiation beam, comprising:

(a) determining, based on known spectral and intensity characteristics of a source beam along the treatment beam paths and from coordinates of the lesion in the aligned patient-eye position, a total treatment time for irradiation along the beam paths that is effective to produce a desired radiation dose at the lesion; and

(b) determining, based on known spectral and intensity characteristics of the source beam along the beam paths and from coordinates of the optic nerve in the aligned patient-eye position, an extent and duration of eye movement, away from the aligned patient-eye position in a direction that moves the patient'"'"'s optic nerve toward the irradiation beam, that will be allowed during treatment, while maintaining the radiation dose at the patient optic nerve below a predetermined dose level.

12. The medium of claim 11, wherein the retinal lesion includes one of macular degeneration, drusen, a tumor, and a vascular abnormality, and further comprising determining the coordinates of the lesion and the optic nerve in an external coordinate system.

13. The medium of claim 12, wherein the retinal lesion comprises macular degeneration, and further comprising determining coordinates of the macula and the optic nerve in an external coordinate system.

14. The medium of claim 11, which is operable to determine, for the source of collimated x-radiation beam,

(i) at least one of a beam-source collimator configuration that is based on an X-ray emission source-to-target distance, a collimator exit aperture-to-body surface distance, an emission or anode source size, and a collimator exit aperture size that is calculated to provide an X-ray beam-spot at the retina having a diameter or characteristic dimension to the 80% isodose of less than about 8 mm or a penumbra width between the 80% isodose and the 20% isodose of less than about 40% of the beam-spot diameter or beam spot characteristic dimension;

and

(ii) a maximum photon energy and a beam filtration configuration to provide a maximum photon energy between 25-150 keV.

15. The medium of claim 11, which is operable, based on a measured ocular dimension of the patient'"'"'s eye, to (i) determine a model of the eye that includes the coordinates of eye features, including the macula and optic nerve, and a virtual ocular medium to the measured ocular dimension, and (ii) determine, from a known distance of travel of the beam within the model along each path and from the virtual ocular medium through which the beam travels, the dose of radiation from the source to be delivered along each path to produce the desired radiation dose at the macula of the patient'"'"'s eye.

16. A system for planning a treatment for a lesion on or adjacent to the retina of an eye of a patient, by directing a radiation beam at the lesion in a patient'"'"'s eye, comprising:

(a) a device for aligning the patient eye,

(b) a processor configured to receive coordinates of an aligned patient-eye position in an external coordinate system, and that stores information effective for determining, from the received coordinates, coordinates of the lesion and optic nerve in the patient eye, and

(c) a machine-readable medium which operates with the processor to execute machine-readable instructions for performing the steps of;

(i) determining, based on known spectral and intensity characteristics of a source beam along established beam paths, directed from a source of a collimated x-radiation beam at the lesion, and from the coordinates of the lesion in the aligned patient-eye position, a total treatment time for irradiation along the beam paths that is effective to produce a desired radiation dose at the lesion, and

(ii) determining, based on known spectral and intensity characteristics of the source beam along the established beam paths and from the coordinates of the optic nerve in the aligned patient-eye position, the extent and duration of eye movement, away from the aligned patient-eye position in a direction that moves the patient'"'"'s optic nerve toward the irradiation beam, that will be allowed during treatment while maintaining the radiation dose at the patient optic nerve below a predetermined dose level.

17. The system of claim 16, wherein the retinal lesion includes one of macular degeneration, drusen, a retinal tumor, and a retinal vascular abnormality;

and step (c)(ii) further comprises determining the coordinates of the lesion and the optic nerve in an external coordinate system.

18. The system of claim 17, wherein the retinal lesion includes macular degeneration, and step (c)(ii) further comprises determining coordinates of the macula and the optic nerve in an external coordinate system.

19. The system of claim 17, wherein the medium is operable to determine, for the source of collimated x-radiation beam,

(i) at least one of a beam-source collimator configuration that is based on an X-ray emission source-to-target distance, a collimator exit aperture-to-body surface distance, an emission or anode source size, and a collimator exit aperture size that is calculated to provide an X-ray beam-spot at the retina having a diameter or characteristic dimension to the 80% isodose of less than about 8 mm or a penumbra width between the 80% isodose and the 20% isodose of less than about 40% of the beam-spot diameter or beam spot characteristic dimension;

and

(ii) a maximum photon energy and a beam filtration configuration to provide a maximum photon energy between 25-150 keV.

20. The system of claim 19, wherein the medium is operable, in performing step (b) and based on a measured ocular dimension of the patient'"'"'s eye, to (i) determine a model of the eye that includes the coordinates of eye features, including the macula and optic nerve, and a virtual ocular medium to the measured ocular dimension, and (ii) determine, from a known distance of travel of the beam within the model along each path and from the virtual ocular medium through which the beam travels, the dose of radiation from the source to be delivered along each path to produce the desired radiation dose at the macula of the patient'"'"'s eye.